In the international, randomized, double-blind, phase III CLEOPATRA trial, the addition of pertuzumab to trastuzumab plus docetaxel was studied in patients with newly metastatic HER2-positive breast cancer, 40–47% of who received previous trastuzumab [22]. The gene discussed is ERBB2; the disease is breast cancer.